Liposomal extended-release bupivacaine for postsurgical analgesia

Figures & data

Table 1 Comparison between EXPAREL® and bupivacaine HCl

Formulation	Costs	Pain intensity scores	Time until opioid rescue (h)	% adverse events
EXPAREL®	$14.25/20 mL	283*, 441.5†	10*, 19#	9–20%π, 62%λ
Bupivacaine HCl	$0.291/10 mL	329*, 468.3†	3*, 8#	8–19%π, 43%λ

Notes:

π Baxter et al;¹⁸

λ Viscusi et al;¹⁹

* Dasta et al;²⁰

# Haas et al;²¹

† Smoot et al.²³

Abbreviation: HCl, hydrochloride.

BaxterRBramlettKOnelEDanielsSImpact of local administration of liposome bupivacaine for postsurgical analgesia on wound healing: a review of data from ten prospective, controlled clinical studiesClin Ther2013353312320. e523453403

 PubMed Web of Science ®Google Scholar

ViscusiERSinatraROnelERamamoorthySLThe safety of liposome bupivacaine, a novel local analgesic formulationClin J Pain Epub2262013

 Web of Science ®Google Scholar

DastaJRamamoorthySPatouGSinatraRBupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical settingCurr Med Res Opin201228101609161522900785

 PubMed Web of Science ®Google Scholar

HaasEOnelEMillerHRagupathiMWhitePFA double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulationAm Surg201278557458122546131

 PubMed Web of Science ®Google Scholar

SmootJDBergeseSDOnelEWilliamsHTHeddenWThe efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: a randomized, doubleblind, active-control studyAesthet Surg J2012321697622179931

 PubMed Web of Science ®Google Scholar